313 related articles for article (PubMed ID: 20868235)
1. Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice.
Martin IV; Schmitt J; Minkenberg A; Mertens JC; Stieger B; Mullhaupt B; Geier A
Biol Chem; 2010 Dec; 391(12):1441-9. PubMed ID: 20868235
[TBL] [Abstract][Full Text] [Related]
2. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis.
Mencarelli A; Renga B; Migliorati M; Cipriani S; Distrutti E; Santucci L; Fiorucci S
J Immunol; 2009 Nov; 183(10):6657-66. PubMed ID: 19880446
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.
Yang F; Huang X; Yi T; Yen Y; Moore DD; Huang W
Cancer Res; 2007 Feb; 67(3):863-7. PubMed ID: 17283114
[TBL] [Abstract][Full Text] [Related]
4. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S
Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563
[TBL] [Abstract][Full Text] [Related]
5. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
Cariou B
Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
[TBL] [Abstract][Full Text] [Related]
6. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver.
Zollner G; Wagner M; Fickert P; Geier A; Fuchsbichler A; Silbert D; Gumhold J; Zatloukal K; Kaser A; Tilg H; Denk H; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G798-805. PubMed ID: 16002565
[TBL] [Abstract][Full Text] [Related]
7. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus.
Capello A; Moons LM; Van de Winkel A; Siersema PD; van Dekken H; Kuipers EJ; Kusters JG
Am J Gastroenterol; 2008 Jun; 103(6):1510-6. PubMed ID: 18510604
[TBL] [Abstract][Full Text] [Related]
8. Role of bile acids and bile acid receptors in metabolic regulation.
Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
Martínez-Fernández P; Hierro L; Jara P; Alvarez L
Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
[TBL] [Abstract][Full Text] [Related]
10. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents.
Boyer JL; Trauner M; Mennone A; Soroka CJ; Cai SY; Moustafa T; Zollner G; Lee JY; Ballatori N
Am J Physiol Gastrointest Liver Physiol; 2006 Jun; 290(6):G1124-30. PubMed ID: 16423920
[TBL] [Abstract][Full Text] [Related]
12. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression.
Sekiya M; Yahagi N; Matsuzaka T; Najima Y; Nakakuki M; Nagai R; Ishibashi S; Osuga J; Yamada N; Shimano H
Hepatology; 2003 Dec; 38(6):1529-39. PubMed ID: 14647064
[TBL] [Abstract][Full Text] [Related]
13. VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium.
Chignard N; Mergey M; Barbu V; Finzi L; Tiret E; Paul A; Housset C
Hepatology; 2005 Sep; 42(3):549-57. PubMed ID: 16037943
[TBL] [Abstract][Full Text] [Related]
14. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.
Wagner M; Halilbasic E; Marschall HU; Zollner G; Fickert P; Langner C; Zatloukal K; Denk H; Trauner M
Hepatology; 2005 Aug; 42(2):420-30. PubMed ID: 15986414
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease.
Hong F; Radaeva S; Pan HN; Tian Z; Veech R; Gao B
Hepatology; 2004 Oct; 40(4):933-41. PubMed ID: 15382116
[TBL] [Abstract][Full Text] [Related]
16. The bile acid receptor FXR is a modulator of intestinal innate immunity.
Vavassori P; Mencarelli A; Renga B; Distrutti E; Fiorucci S
J Immunol; 2009 Nov; 183(10):6251-61. PubMed ID: 19864602
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
Jiang T; Wang XX; Scherzer P; Wilson P; Tallman J; Takahashi H; Li J; Iwahashi M; Sutherland E; Arend L; Levi M
Diabetes; 2007 Oct; 56(10):2485-93. PubMed ID: 17660268
[TBL] [Abstract][Full Text] [Related]
18. 1Alpha,25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo.
Chow EC; Durk MR; Cummins CL; Pang KS
J Pharmacol Exp Ther; 2011 Jun; 337(3):846-59. PubMed ID: 21421739
[TBL] [Abstract][Full Text] [Related]
19. FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.
Mencarelli A; Cipriani S; Renga B; D'Amore C; Palladino G; Distrutti E; Baldelli F; Fiorucci S
Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):94-101. PubMed ID: 21924881
[TBL] [Abstract][Full Text] [Related]
20. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]